Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multicenter, mechanism validation study to evaluate the safety, efficacy and tolerability of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV-1-infected subjects.

Next Previous
X
Search
Trial Profile

An open-label, multicenter, mechanism validation study to evaluate the safety, efficacy and tolerability of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV-1-infected subjects.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KP 1461 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational
  • Sponsors Koronis Pharmaceuticals

    • Most Recent Events

    • 04 Nov 2011 Planned end date changed from 1 Dec 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Results published in the PLoS One Journal (January 14), according to a Koronis Pharmaceuticals media release
    • 12 Nov 2008 Status changed from active, no longer recruiting to discontinued, as reported in ClinicalTrials.gov records, citing "Corroboration of supporting in vitro data".

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top